Pharmaceutical Investing Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
AMENDED FROM SOURCE - Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
